First-line therapy for young patients with CLL

Nitin Jain; Susan O'Brien

doi:10.1182/asheducation-2016.1.146

First-line therapy for young patients with CLL

Nitin Jain, Susan O'Brien

Leukemia

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

A 61-year-old man with a history of chronic lymphocytic leukemia (CLL) presents with complaints of worsening fatigue and night sweats. He was diagnosed with CLL 3 years ago on routine blood count testing. He has no major medical comorbidities. On examination, he has several 2- to 3-cm lymph nodes in the cervical and axillary area. Spleen is palpable 5 cm below the costal margin. Blood counts show lymphocytosis with thrombocytopenia and anemia. Prognostic markers include deletion 13q by fluorescence in situ hybridization analysis and mutated IGHV. You are asked by the hematology fellow you are supervising about the best treatment of this patient.

Original language	English (US)
Pages (from-to)	146-148
Number of pages	3
Journal	Hematology
Volume	2016
Issue number	1
DOIs	https://doi.org/10.1182/asheducation-2016.1.146
State	Published - 2016

ASJC Scopus subject areas

Hematology

Access to Document

10.1182/asheducation-2016.1.146

Cite this

@article{86f5f7fd99ff445ca58d3ff224d10386,

title = "First-line therapy for young patients with CLL",

abstract = "A 61-year-old man with a history of chronic lymphocytic leukemia (CLL) presents with complaints of worsening fatigue and night sweats. He was diagnosed with CLL 3 years ago on routine blood count testing. He has no major medical comorbidities. On examination, he has several 2- to 3-cm lymph nodes in the cervical and axillary area. Spleen is palpable 5 cm below the costal margin. Blood counts show lymphocytosis with thrombocytopenia and anemia. Prognostic markers include deletion 13q by fluorescence in situ hybridization analysis and mutated IGHV. You are asked by the hematology fellow you are supervising about the best treatment of this patient.",

author = "Nitin Jain and Susan O'Brien",

note = "Funding Information: Conflict-of-interest disclosure: S.O. has received research funding from Pharmacyclics, LLC, an AbbVie Company and has consulted for and received honoraria fromPharmacyclics,LLC,anAbbVieCompanyandJanssen.N.J.hasreceivedresearchfundingfromPharmacyclics,LLC,anAbbVieCompanyandGenentechandhas consulted for and received honoraria from Pharmacyclics, LLC, an AbbVie Company.",

year = "2016",

doi = "10.1182/asheducation-2016.1.146",

language = "English (US)",

volume = "2016",

pages = "146--148",

journal = "Hematology",

issn = "1520-4391",

number = "1",

}

TY - JOUR

T1 - First-line therapy for young patients with CLL

AU - Jain, Nitin

AU - O'Brien, Susan

N1 - Funding Information: Conflict-of-interest disclosure: S.O. has received research funding from Pharmacyclics, LLC, an AbbVie Company and has consulted for and received honoraria fromPharmacyclics,LLC,anAbbVieCompanyandJanssen.N.J.hasreceivedresearchfundingfromPharmacyclics,LLC,anAbbVieCompanyandGenentechandhas consulted for and received honoraria from Pharmacyclics, LLC, an AbbVie Company.

PY - 2016

Y1 - 2016

N2 - A 61-year-old man with a history of chronic lymphocytic leukemia (CLL) presents with complaints of worsening fatigue and night sweats. He was diagnosed with CLL 3 years ago on routine blood count testing. He has no major medical comorbidities. On examination, he has several 2- to 3-cm lymph nodes in the cervical and axillary area. Spleen is palpable 5 cm below the costal margin. Blood counts show lymphocytosis with thrombocytopenia and anemia. Prognostic markers include deletion 13q by fluorescence in situ hybridization analysis and mutated IGHV. You are asked by the hematology fellow you are supervising about the best treatment of this patient.

AB - A 61-year-old man with a history of chronic lymphocytic leukemia (CLL) presents with complaints of worsening fatigue and night sweats. He was diagnosed with CLL 3 years ago on routine blood count testing. He has no major medical comorbidities. On examination, he has several 2- to 3-cm lymph nodes in the cervical and axillary area. Spleen is palpable 5 cm below the costal margin. Blood counts show lymphocytosis with thrombocytopenia and anemia. Prognostic markers include deletion 13q by fluorescence in situ hybridization analysis and mutated IGHV. You are asked by the hematology fellow you are supervising about the best treatment of this patient.

UR - http://www.scopus.com/inward/record.url?scp=85021848021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021848021&partnerID=8YFLogxK

U2 - 10.1182/asheducation-2016.1.146

DO - 10.1182/asheducation-2016.1.146

M3 - Article

C2 - 27913473

AN - SCOPUS:85021848021

SN - 1520-4391

VL - 2016

SP - 146

EP - 148

JO - Hematology

JF - Hematology

IS - 1

ER -

First-line therapy for young patients with CLL

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this